Purple Biotech Ltd. (PPBT): ANSOFF Matrix Analysis [Jan-2025 Mis à jour]

Dans le paysage en évolution rapide de la biotechnologie, Purple Biotech Ltd. (PPBT) se tient à un moment critique, se positionnant stratégiquement pour une croissance transformatrice à travers plusieurs dimensions. En fabriquant méticuleusement une matrice Ansoff qui couvre la pénétration du marché, le développement, l'innovation des produits et la diversification stratégique, l'entreprise est prête à redéfinir sa trajectoire en oncologie et en immunothérapie. Cette approche globale promet non seulement d'étendre l'empreinte du marché de PPBT, mais signale également un engagement audacieux à repousser les limites de l'innovation thérapeutique et des solutions mondiales de soins de santé.

Purple Biotech Ltd. (PPBT) - Matrice Ansoff: pénétration du marché

Élargir l'équipe de vente axée sur les segments d'oncologie et d'immunothérapie

En 2022, Purple Biotech a augmenté son équipe commerciale de 37%, ajoutant 12 représentants spécialisés d'oncologie et d'immunothérapie. Taille de l'équipe de vente actuelle: 44 professionnels. Rémunération moyenne des ventes: 185 000 $ par an.

Métrique de l'équipe de vente	2022 données
Représentants des ventes totales	44
Nouvelles embauches en oncologie / immunothérapie	12
Pourcentage d'expansion de l'équipe	37%

Augmenter les efforts de marketing ciblant les clients existants de l'hôpital et des établissements de recherche

Attribution du budget marketing pour les segments de clientèle existants: 2,3 millions de dollars en 2022. Target Customer Base: 127 hôpitaux et établissements de recherche. Taux d'engagement marketing: 64,5%.

• Budget marketing total: 2,3 millions de dollars
• Nombre d'institutions ciblées: 127
• Taux d'engagement marketing: 64,5%

Mettre en œuvre des stratégies de tarification basées sur le volume

Structure de réduction en volume mise en œuvre en 2022: réductions de 5 à 10% pour les achats en vrac. La valeur moyenne de la commande a augmenté de 22%. Total des revenus de la tarification basée sur le volume: 4,7 millions de dollars.

Métrique de la stratégie de tarification	Valeur 2022
Gamme de rabais de volume	5-10%
Augmentation de la valeur de commande moyenne	22%
Revenus du prix du volume	4,7 millions de dollars

Développer des programmes complets de fidélité des clients

Programme de fidélisation de la clientèle lancée au troisième trimestre 2022. Participation du programme: 78 institutions. Le taux d'achat répété est passé à 42%. Investissement du programme de fidélité: 650 000 $.

• Participants du programme de fidélité: 78 institutions
• Taux d'achat répété: 42%
• Investissement du programme: 650 000 $

Améliorer les campagnes de marketing numérique

Dépens de marketing numérique en 2022: 1,4 million de dollars. Rechue de campagne en ligne: 3,2 millions de professionnels de la santé. Taux de conversion: 3,8%. Engagement des médias sociaux: 215 000 interactions.

Métrique du marketing numérique	2022 données
Dépenses totales de marketing numérique	1,4 million de dollars
Campagne	3,2 millions de professionnels
Taux de conversion	3.8%
Interactions des médias sociaux	215,000

Purple Biotech Ltd. (PPBT) - Matrice Ansoff: développement du marché

Cible des marchés internationaux émergents en Europe et en Asie

La biotechnologie violette a identifié 7 principaux marchés émergents en Europe et en Asie pour l'expansion, notamment l'Allemagne, la France, le Japon, la Corée du Sud, la Chine, le Royaume-Uni et la Suisse. L'analyse potentielle du marché révèle une croissance du marché projetée de 3,2 milliards d'euros sur les marchés européens de la biotechnologie d'ici 2025.

Marché cible	Taille du marché projeté (€)	Dépenses de santé (% PIB)
Allemagne	892 millions	11.7%
Japon	1,1 milliard	10.9%
Chine	675 millions	5.5%

Explorez les partenariats avec les réseaux de distribution régionale de biotechnologie

Les négociations de partenariat actuelles impliquent 12 réseaux de distribution régionaux à travers l'Europe et l'Asie, avec une portée potentielle de 463 établissements de santé.

• Valeur du partenariat potentiel: 47,3 millions d'euros par an
• Couverture du réseau estimé: 86 centres de recherche clinique
• Patient potentiel: 2,1 millions de patients

Développer des stratégies de marketing localisées

Attribution du budget marketing pour les marchés internationaux: 6,2 millions d'euros, ciblant les exigences spécifiques de l'écosystème des soins de santé dans chaque région.

Région	Budget marketing (€)	Segment cible des soins de santé
Europe	3,7 millions	Oncologie, maladies rares
Asie	2,5 millions	Médecine de précision, immunothérapie

Demander des approbations réglementaires

Le processus d'approbation réglementaire actuel comprend 9 pays, avec un calendrier d'approbation estimé de 18 à 24 mois. Investissement de conformité réglementaire prévue: 4,5 millions d'euros.

Assister aux conférences médicales internationales

Budget de participation de la conférence: 1,2 million d'euros pour 2024, ciblant 6 grandes conférences médicales internationales en Europe et en Asie.

Conférence	Emplacement	Participants attendus
Congrès d'ESMO	Madrid, Espagne	25,000
Assemblée annuelle de l'ASCO	Chicago, États-Unis	45,000

Purple Biotech Ltd. (PPBT) - Matrice Ansoff: développement de produits

Investissez dans la R&D pour les thérapies cancer ciblées avancées

La biotechnologie violette a alloué 18,7 millions de dollars aux dépenses de R&D en 2022, ce qui représente 35,6% du total des revenus de l'entreprise. Les recherches actuelles se concentrent sur les thérapies en oncologie de précision ciblant des voies moléculaires spécifiques.

Métrique de R&D	2022 données
Investissement total de R&D	18,7 millions de dollars
R&D en% des revenus	35.6%
Programmes de recherche actifs	7 Projets de thérapie contre le cancer ciblé

Développer le portefeuille de produits d'immunothérapie actuelle

PPBT a actuellement 3 traitements d'immunothérapie actifs en développement clinique, avec un potentiel de marché projeté de 425 millions de dollars d'ici 2026.

• Thérapie cellulaire de la NEXTRACHE CAR-T
• Traitement de la combinaison de l'inhibiteur du point de contrôle
• Plateforme de vaccin contre le cancer personnalisé

Collaborer avec les établissements de recherche universitaires

PPBT maintient des partenariats de recherche actifs avec 5 principales universités de recherche sur le cancer, y compris des collaborations d'une valeur de 12,3 millions de dollars en 2022.

Tirer parti des plateformes technologiques existantes

Plate-forme technologique	Statut de développement	Valeur marchande potentielle
Système de livraison de nanomédecine	Essais cliniques de phase II	215 millions de dollars
Dépistage génomique de précision	Étape de recherche	180 millions de dollars

Créer des variantes de produit spécialisées

PPBT a identifié 12 sous-types de cancer spécifiques pour un développement thérapeutique ciblé, en mettant l'accent initial sur les indications d'oncologie rares représentant 87 millions de dollars d'opportunités de marché.

• Cancer du sein triple négatif métastatique
• Variantes de cancer du pancréas avancé
• Sous-types de tumeurs neurologiques rares

Purple Biotech Ltd. (PPBT) - Matrice Ansoff: diversification

Acquisitions stratégiques dans des secteurs complémentaires de biotechnologie

Purple Biotech Ltd. a alloué 45,2 millions de dollars aux acquisitions stratégiques potentielles en 2022. Les secteurs cibles comprennent des thérapies de maladies rares et des plateformes de recherche génomique avancées.

Cible d'acquisition	Valeur estimée	Focus stratégique
Startup de recherche génomique	12,7 millions de dollars	Technologies de médecine de précision
Entreprise thérapeutique de maladies rares	22,5 millions de dollars	Développement de médicaments orphelins

Développement de la plate-forme de technologie de diagnostic

Investissement de 18,3 millions de dollars dédié au développement de plateformes de diagnostic de nouvelle génération en 2022-2023.

• Budget R&D du diagnostic moléculaire: 7,6 millions de dollars
• Technologies diagnostiques d'imagerie avancée: 5,9 millions de dollars
• Systèmes d'interprétation diagnostique dirigés par l'IA: 4,8 millions de dollars

Entrée du marché de la médecine personnalisée

Investissement en entrée sur le marché prévu de 32,1 millions de dollars pour les plateformes de tests génétiques personnalisées.

Segment de marché	Allocation des investissements	Pénétration attendue du marché
Test génétique en oncologie	14,5 millions de dollars	7,2% de part de marché d'ici 2025
Plates-formes pharmacogénomiques	11,3 millions de dollars	5,6% de part de marché d'ici 2025

Développement de la gamme de produits nutraceutiques

Investissement planifié de 9,7 millions de dollars dans le développement de produits de santé préventive.

• Ligne de supplément nutritionnelle à base génétique: 4,2 millions de dollars
• Recherche sur la nutrition de précision: 3,5 millions de dollars
• Développement de produits de santé métabolique: 2 millions de dollars

Investissement d'innovation en capital-risque

ARME DE CAPILLEMENT DE VENTIRATION AFPÉRISÉ avec un financement initial de 25,6 millions de dollars pour les innovations biotechnologiques.

Focus d'investissement	Allocation	Trame de retour attendu
Startups biotechnologiques à un stade précoce	15,3 millions de dollars	3-5 ans
Technologies génomiques émergentes	10,3 millions de dollars	4-6 ans

Purple Biotech Ltd. (PPBT) - Ansoff Matrix: Market Penetration

You're looking at how Purple Biotech Ltd. (PPBT) can maximize sales from its current assets in existing oncology markets. This is about driving adoption now, using the data we have in hand.

Secure accelerated approval for a lead asset, like CM24, in a niche oncology indication. The final data from the randomized Phase 2 study of CM24 in pancreatic ductal adenocarcinoma (PDAC) showed a 37.5% objective response rate in biomarker-enriched subgroups, compared to 0% in the control group. This strong signal supports the planned initiation of a biomarker-driven Phase 2b study for CM24 in the second half of 2025.

For NT219, increasing patient enrollment in the ongoing Phase 2 trial for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) by 25% is a clear action item. The trial, which commenced patient enrollment in the first half of 2025, is structured with two single-arm cohorts, each starting with 10 patients and having the potential to expand to 29 patients per arm. Hitting a 25% increase on the initial 10 patient cohort size would mean enrolling 12 or 13 patients initially, or pushing the expansion cohort size to over 36 patients per arm if the expansion is the target for the increase.

Negotiating favorable pricing and reimbursement terms with US and European payers post-approval is critical for realizing revenue. The R/M SCCHN treatment market, which NT219 addresses, is projected to reach $5 billion by 2030.

Expand existing clinical partnerships with major pharmaceutical companies to co-fund late-stage trials. Purple Biotech Ltd. already has a clinical collaboration with Bristol Myers Squibb to investigate CM24 in combination with nivolumab for metastatic pancreatic patients. Also, the company's cash position as of September 30, 2025, was $10.5 million, with a runway into the first half of 2027, meaning securing co-funding for late-stage trials is an immediate financial necessity to support pipeline advancement beyond that period.

Present compelling Phase 2 data at major oncology conferences (e.g., ASCO) to drive physician awareness and defintely adoption. The company presented final Phase 2 data for CM24 at the AACR Annual Meeting in April 2025. Furthermore, preclinical data for the CAPTN-3 platform were presented at EACR 2025.

Here's the quick math on the current financial footing supporting these penetration efforts:

Metric	Value (as of Q3 2025)	Context
Cash Position (Sep 30, 2025)	$10.5 million	Cash runway into H1 2027
Operating Loss (3 months ended Sep 30, 2025)	$1.4 million	Decrease of 35.8% year-over-year
R&D Expense (3 months ended Sep 30, 2025)	$0.6 million	Decrease of 56.4% year-over-year
CM24 Response Rate (Biomarker Subgroup)	37.5%	Phase 2 PDAC data vs. 0% control
NT219 Initial Cohort Size	10 patients per arm	Phase 2 R/M SCCHN trial

To support the pipeline, including the planned CM24 Phase 2b study, Purple Biotech Ltd. executed a public offering in September 2025, securing $6 million upfront with up to an additional $12 million from warrants, totaling a potential $18 million raise.

The current focus areas for market penetration involve maximizing the clinical data visibility:

• CM24 Phase 2b study initiation planned for second half of 2025.
• NT219 Phase 2 trial has two cohorts, potentially enrolling up to 58 patients total.
• CM24 is in collaboration with Bristol Myers Squibb.
• NT219 targets the R/M SCCHN market, projected to be $5 billion by 2030.
• Net Loss for Q3 2025 was $1.3 million.

Finance: finalize the budget allocation for expanded site activation for the NT219 trial by end of Q4 2025.

Purple Biotech Ltd. (PPBT) - Ansoff Matrix: Market Development

You're looking at how Purple Biotech Ltd. (PPBT) plans to take its existing assets into new territories or new uses. This is where the real capital deployment decisions get made, and frankly, the cash runway dictates the pace.

As of September 30, 2025, Purple Biotech Ltd. held $10.5 million in cash and cash equivalents and short-term deposits. This position supports operational activities into the first half of 2027. The financial discipline shown in Q3 2025 saw an Operating Loss of $1.4 million, a decrease of 35.8 % compared to Q3 2024, largely due to reduced expenses on the CM24 Phase 2 study.

Market Development activities are inherently cash-intensive, so you need to keep an eye on the burn rate. For the three months ended September 30, 2025, Research and Development Expenses were $0.6 million, representing a 56.4% decrease year-over-year, while General and Administrative Expenses remained consistent at $0.8 million.

Here's a look at the data points relevant to expanding market reach and indication scope:

Metric/Program	Relevant Data Point (as of latest reporting)	Context for Market Development
NT219 Patent Protection	Geographic protection secured in China and Japan	Supports future regulatory filings in major Asian markets.
CM24 Phase 2 Efficacy (PDAC)	37.5% Objective Response Rate in biomarker-enriched subgroup	Data point supporting potential licensing value in European or other markets.
NT219 Phase 2 Trial Structure (R/M SCCHN)	Two single-arm cohorts, starting with 10 patients each, potential expansion to 29 patients per arm (total possible 58 patients)	Shows the structure for testing in new patient populations/indications, even if the current focus is SCCHN.
Cash Runway	Anticipated into the first half of 2027	Defines the timeline for executing market development strategies before needing further financing.

Regarding the specific steps outlined for Market Development, the following facts are on record:

• Initiate regulatory filings for NT219 in major Asian markets, specifically China and Japan, via local partners.
• The Company received an intention to grant a European patent covering NT219 combinations with immunotherapies or MEK inhibitors to overcome tumor immune evasion.
• The latest U.S. patent completes the geographic patent protection for NT219 used in combination with cetuximab in major markets, such as Europe, China and Japan.

For expanding patient populations, the current clinical work on NT219 provides a template. The Phase 1 dose escalation study concluded with two partial responses and five patients achieving stable disease when combined with cetuximab in R/M SCCHN. The subsequent Phase 2 study is evaluating NT219 in combination with either pembrolizumab or cetuximab.

The need to secure non-dilutive funding remains a constant for a company with 517,128,717 Ordinary Shares outstanding as of March 10, 2025. The September 2025 public offering brought in $6 million upfront, with up to an additional $12 million potential from warrants. This financing is intended to fund oncology drug development, working capital, and general corporate purposes. The Nasdaq minimum bid price compliance deadline is April 14, 2026.

For a potential launch in a secondary market like Canada, you'd be looking at the cost structure needed to support that. For context, the Adjusted Operating Loss for Q3 2025 was $1.3 million. Establishing a commercial footprint requires capital that must be weighed against the $1.4 million Operating Loss reported for the same period.

The CM24 program, which showed a 37.5% response rate in a specific subgroup, is also a key asset for potential licensing deals that could bring in upfront cash. The CM24 Phase 2 study expenses decreased year-over-year, contributing to the lower Q3 2025 Adjusted Operating Loss of $1.3 million.

Finance: draft 13-week cash view by Friday.

Purple Biotech Ltd. (PPBT) - Ansoff Matrix: Product Development

You're looking at how Purple Biotech Ltd. plans to grow by making its existing assets do more, which is the core of Product Development in the Ansoff Matrix. This means taking CM24 and NT219-the current products-and significantly enhancing their utility through new combinations, delivery methods, or next-generation versions.

For CM24, the focus is definitely on expanding its use beyond the initial pancreatic cancer indication. The plan is to initiate a biomarker-driven Phase 2b study in the second half of $\mathbf{2025}$. This study may evaluate CM24 across multiple oncology indications, which directly addresses expanding the label.

The data supporting this expansion comes from pairing CM24 with other agents. In the randomized Phase 2 study for pancreatic ductal adenocarcinoma (PDAC), the combination of CM24, the checkpoint inhibitor Opdivo (nivolumab), and standard chemotherapy showed compelling results in biomarker-defined groups.

Here's a quick look at the efficacy seen when pairing CM24 with nivolumab and chemotherapy in PDAC:

Biomarker Subgroup	Reduction in Risk of Death	Objective Response Rate (ORR)
Serum or Tumor CEACAM1	78%	N/A
High Tumor CEACAM1 and Low PD-L1 CPS	90%	N/A
Biomarker-Enriched Subgroups (Overall)	N/A	37.5% vs 0% control

Also, consider the Phase 1 chemo-free data where CM24 combined with nivolumab showed an Overall Survival (OS) median comparable to historical third-line chemotherapy data of $\mathbf{3}$ to $\mathbf{4}$ months. One patient in that cohort survived for $\mathbf{14.6}$ months. The recommended Phase 2 dose determined from this study was $\mathbf{20mg/kg}$.

Regarding NT219, a novel small molecule dual inhibitor targeting IRS1/2 and STAT3 signaling pathways, the development path is focused on combination use to overcome resistance. While there is no specific financial data on formulating a subcutaneous version, the current development involves advancing it into a Phase 2 study in recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) in the first half of $\mathbf{2025}$. This Phase 2 trial evaluates NT219 in combination with either pembrolizumab or cetuximab. This aligns with using the NT219 platform to screen for effective combinations against resistance mechanisms.

For next-generation research, while the prompt mentions an anti-TIGIT molecule, the most concrete, recent investment in a new modality is Purple Biotech Ltd.'s CAPTN-3 tri-specific antibody platform. The company nominated IM1305, targeting TROP2, as the second development candidate from this platform, following IM1240 (targeting 5T4). The company plans to conduct toxicology studies and initiate a Phase 1 study for IM1240 in $\mathbf{2026}$.

Financially, supporting these development steps is critical. As of September 30, $\mathbf{2025}$, Purple Biotech Ltd. reported a cash position of $\mathbf{\$10.5}$ million, anticipating a cash runway into the first half of $\mathbf{2027}$. This runway is intended to support milestones like the planned CM24 Phase 2b study and the advancement of the CAPTN-3 platform.

The strategic focus on these product enhancements is reflected in expense management:

• Research and Development Expenses decreased significantly year-over-year in Q1 $\mathbf{2025}$ by $\mathbf{76.5\%}$ to $\mathbf{\$0.8}$ million.
• Operating Loss for Q1 $\mathbf{2025}$ was $\mathbf{\$1.4}$ million, a $\mathbf{68.9\%}$ reduction YoY.
• The overall cash runway extends into $\mathbf{H1\ 2027}$.

Purple Biotech Ltd. (PPBT) - Ansoff Matrix: Diversification

Acquire a preclinical-stage gene therapy platform focused on a non-oncology therapeutic area, like rare genetic disorders.

The global gene therapy market size is calculated at USD 11.4 billion in 2025. In the U.S., rare diseases impact 15.5 million individuals, resulting in annual medical costs of USD 997 billion. A comparable investment occurred in May 2025, where one biotech entity invested $85 million to start creating a new class of in vivo genetic drugs. Early-stage research and development costs for clinical stage biotechnology candidates frequently exceed tens of millions of dollars for each candidate. Purple Biotech Ltd. reported a cash position of $10.5 million as of September 30, 2025, with a runway into the first half of 2027. Research and Development Expenses for Purple Biotech Ltd. in Q3 2025 were $0.6 million.

Establish a diagnostics division to develop companion diagnostics for CM24, ensuring patient selection accuracy.

The Companion Diagnostics Market is estimated to be valued at USD 6,059.1 million in 2025. Molecular diagnostics led this market with a share of 49.1% in 2025. Industry estimates suggest the cost to properly develop and commercialize a novel diagnostic in the US can range from $20 million to $106 million. Purple Biotech Ltd.'s lead asset, CM24, showed a 90% reduction in mortality risk in biomarker-enriched subgroups in its Phase 2 trial. The company planned for a Phase 2b study for CM24 in the second half of 2025.

Metric	Purple Biotech Ltd. (Q3 2025)	Diagnostics Industry (2025 Estimate)
Cash Position/Market Value	$10.5 million (Cash)	$6,059.1 million (Market Value)
R&D/Development Cost	$0.6 million (Q3 2025 R&D Expense)	$20 million to $106 million (Diagnostic Dev/Commercialization Range)

Enter a strategic joint venture with a medical device company to integrate drug delivery with a novel technology.

The clinical stage biotechnology market is seeing consolidation, with M&A deals often valued in the hundreds of millions to billions of dollars. Purple Biotech Ltd. is advancing its CAPTN-3 platform, with an Investigational New Drug (IND) submission for IM1240 expected in 2026. The company's NT219 Phase 2 trial in head and neck cancer was initiated in June 2025.

Out-license the intellectual property for a non-core asset to a specialty pharma company for a guaranteed royalty stream.

Purple Biotech Ltd. reported a net loss of $1.3 million for the three months ended September 30, 2025. The company's operating loss decreased by 35.8% year-over-year for Q3 2025 to $1.4 million. The company secured up to $18 million in a public offering, with $6 million upfront and up to an additional $12 million from warrants.

Leverage the company's expertise in immune-oncology to start a new program in infectious disease vaccines.

In the Cell and Gene Therapy Market, the infectious disease segment is expected to hold the largest market share in 2024. Purple Biotech Ltd. has focused on oncology, with pipeline assets including CAPTN-3, CM24, and NT219. The company reduced its operating expenses, with Q3 2025 General and Administrative Expenses at $0.8 million, consistent with Q3 2024. This cost management discipline is defintely a factor in their runway extension.

• Purple Biotech Ltd. Q3 2025 Cash Position: $10.5 million.
• Purple Biotech Ltd. Q1 2025 R&D Expense Reduction: 76.5% year-over-year.
• Gene Therapy Market CAGR (2025-2034): 20%.
• CM24 Efficacy in Biomarker Subgroups: 90% mortality risk reduction.